Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
COREG CR vs PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Propranolol is a non-selective beta-adrenergic receptor antagonist blocking beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and renin release; hydrochlorothiazide is a thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
Propranolol hydrochloride 40-80 mg/hydrochlorothiazide 25-50 mg orally twice daily. Maximum propranolol 640 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Propranolol: 3-6 hours (terminal half-life); can increase with hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal half-life); prolonged in renal impairment.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Propranolol: <1% excreted unchanged in urine; extensively metabolized in liver, metabolites excreted renally. Hydrochlorothiazide: ≥95% excreted unchanged in urine via renal tubular secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker